Histogen Inc.
Histogen is a regenerative medicine company focused on developing patented, innovative technologies for aesthetic and therapeutic markets that replace and regenerate tissues in the body. The Company currently has three product candidates in clinical development intended to address what Histogen believes to be underserved, multi-billion dollar global markets: a treatment for hair loss, a dermal filler and a treatment for joint cartilage repair. Histogen’s executive management team has decades of experience in bringing cell-based regenerative products from concept to market. In addition, the Company’s Board of Directors and scientific advisors are leaders in the fields of regenerative medicine and global marketing and business operations. Histogen has brought on experienced consultants to advise the team in regulatory, quality and production areas.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2007
About us
Histogen is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.
History
Histogen, Inc., a Delaware Corporation, was founded in 2007. The Company is focused on developing innovative products based upon Histogen’s unique technology that utilizes the proteins and growth factors produced by cells grown under simulated embryonic conditions. The Company is headquartered in San Diego, California.
Histogen founder Dr. Gail Naughton is a highly respected scientist with extensive experience in the field of tissue engineering and regenerative medicine. Dr. Naughton discovered the potential of proteins and growth factors produced by hypoxia-induced multipotent cells for therapeutic and biomedical applications, and developed Histogen’s unique technology process to create products based on these proteins. The technology is protected by patent families filed in the US and across key geographies.
Our Mission
To redefine regenerative medicine by developing high value therapeutic and aesthetic products that stimulate the body’s own stem cells to regenerate tissues, without the use of embryonic stem cells or animal components.
Business Development
Histogen has a strong commitment to the development of first in class and best in class product applications within various therapeutic and aesthetic areas. As an innovator and a supplier of novel hypoxic- induced biomaterials, we seek (i) to leverage the Company’s core competencies in order to develop products within the field of regenerative medicine, and (ii) to supply partners with our proprietary biomaterials to be incorporated into a broader array of products. In support of this mission, Histogen has made a significant investment in its core team of scientists and engineers, its intellectual property portfolio, and its manufacturing infrastructure.
Histogen’s technology platform produces a multipotent cell conditioned media as well as an extracellular matrix material containing cell-signaling proteins which stimulate stem cells in the body to regenerate tissue. These materials have potential to address what Histogen believes are a number of high value aesthetic applications such as hair growth, skin care and soft tissue fillers. In addition, Histogen believes that these materials hold promise in therapeutic applications including orthopedics and wound healing. Working closely with industry-leading partners and collaborators, Histogen looks to maximize the potential of its proprietary technology platform.
Value Drivers
Histogen is a regenerative medicine company focused on development of innovative products manufactured by hypoxia-induced multipotent stem cells.
Diverse pipeline of product candidates that can be applied to multiple indications, including product candidates that require no third-party reimbursement
Strong patent portfolio
Treatments without the use of embryonic stem cells or animal products